AbbVie Inc. (ABBV) Intrinsic Value & DCF Valuation
Drug Manufacturers - General · NYSE
Current Price
$263.58
Intrinsic Value
$285.52
+7.7% margin of safety
What Is AbbVie Inc.'s Intrinsic Value?
As of 2026-07-29, the base-case DCF model estimates the intrinsic value of AbbVie Inc. (ABBV) at $285.52 per share, compared with a market price of $263.58, a margin of safety of +7.7%. The base case assumes 7.4% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $233.27 to $345.37. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is AbbVie Inc. (ABBV) Undervalued?
At $263.58, ABBV trades about 7.7% below the base-case intrinsic value estimate. That is a real discount, but it stays short of the 30% margin of safety required before calling a stock undervalued.
COMPETITIVE MOAT
↑Dominant Immunology Franchise
AbbVie's Humira and Skyrizi have established strong market positions. The Apogee acquisition further solidifies its leadership in immunology, creating a formidable franchise.
↑Strong Pipeline and R&D
A robust pipeline, particularly in immunology and oncology, provides a continuous stream of potential new blockbusters. This fuels future growth and offsets patent expirations.
↑High Switching Costs for Patients
Once patients are established on AbbVie's therapies, particularly for chronic conditions, switching to a competitor can be difficult and disruptive. This creates patient loyalty.
INVESTMENT RISKS
↓Regulatory Scrutiny and Pricing Pressure
The pharmaceutical industry faces ongoing regulatory scrutiny regarding drug pricing. Government policies and public pressure could impact profitability.
↓Clinical Trial Failures
The success of AbbVie's pipeline is dependent on positive clinical trial outcomes. Any failures could significantly impact future revenue projections.
↓Integration Risk of Acquisitions
While the Apogee acquisition strengthens the moat, integrating new companies and their pipelines carries inherent execution risks. Failure to integrate effectively could hinder value realization.
Base case
ABBV base case valuation
Intrinsic Value
$285.52
Margin of safety
+7.7%
Expected annual return
+1.6%
Base case assumptions: 7.4% annual growth, 10.0% discount rate, 22x exit multiple, 5 year projection. Data as of 2026-07-29.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the ABBV valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for AbbVie Inc. respond.
Open DCF Calculator for ABBVCompany Overview
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Financial Metrics — ABBV Stock Valuation Data
Revenue/Share (TTM)
$35.41
FCF/Share (TTM)
$11.76
ROIC (TTM)
10.3%
ROE (TTM)
-114.2%
P/FCF
22.3x
EV/EBITDA
31.3x
FCF Yield
4.48%
Debt/Equity
n/m
On a trailing twelve-month basis, ABBV generates free cash flow per share of $11.76 alongside a ROIC of 10.3%, both central inputs for a DCF valuation. Its P/FCF ratio of 22.3x and FCF yield of 4.48% then frame how ABBV is priced against peers on a cash flow basis.
Frequently Asked Questions
What is the intrinsic value of ABBV?
AbbVie Inc. currently generates $11.76 in free cash flow per share. At the current price of $263.58, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is ABBV undervalued?
ABBV trades at a P/FCF ratio of 22.3x with a free cash flow yield of 4.48%. This P/FCF is in a moderate range. However, whether ABBV is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value ABBV stock using DCF?
To perform a DCF valuation on AbbVie Inc.: (1) Start with the trailing free cash flow per share ($11.76) as the base, (2) project future FCF growth over 5-10 years based on Drug Manufacturers - General industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting ABBV's risk profile — with a debt-to-equity of -10.95x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to ABBV?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For AbbVie Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Drug Manufacturers - General trends, then discounting those amounts to today's dollars. ABBV's ROIC of 10.3% shows moderate capital returns.
How does WACC affect ABBV stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For ABBV, with a debt-to-equity ratio of -10.95x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 31.3x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See ABBV PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value ABBV with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-07-29. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.